Capstone Investment Advisors
ANIP icon

Capstone Investment Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Capstone Investment Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$923K Buy
11,150
+1,485
+15% +$119K ﹤0.01% 983
2026
Q1 		$743K Sell
9,665
-260
-3% -$20.3K ﹤0.01% 971
2025
Q4 		$783K Buy
+9,925
New +$859K ﹤0.01% 969

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's ANIP Position: Q2 2026 in Review

Capstone Investment Advisors increased its ANI Pharmaceuticals (ANIP) stake by 15% in Q2 2026, buying an estimated $119K and bringing the position to 11,150 shares worth $923K. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Capstone Investment Advisors first reported a position in ANIP in Q4 2025 and has held it in 3 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Capstone Investment Advisors held 11,150 shares of ANI Pharmaceuticals worth $923K as of Q2 2026.
  • Capstone Investment Advisors bought 1,485 ANI Pharmaceuticals shares in Q2 2026, an estimated $119K.
  • ANI Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #983 holding.
  • Capstone Investment Advisors first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.